Cancer researcher Ross B. Mikkelsen, Ph.D., member of the Radiation Biology and Oncology research program at VCU Massey Cancer Center tells his students, “researchers aren’t stupid because we make stupid mistakes, but because we don’t know what’s on the other side of an experiment. On the other hand, when you do find out what’s on the other side, you get a high that you can’t beat.”
2013 brought on some great new research from Massey. Here are the top five stories from the past year: 1. Targeted viral therapy destroys breast cancer stem cells in preclinical experiments 2. Drug combination therapy causes cancer cells to "eat themselves" 3. From head to toe: how to perform a skin self-exam 4. Researchers look to mathematics, nature...
In the December 2013 issue of Our Health Richmond magazine, six Massey physicians were recognized for their kindness, empathy and attentiveness when working with patients. These inaugural Best Bedside Manner Awards seek to recognize professionals who incorporate compassionate care into their practice.
A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme (GBM), the most common and most aggressive form of brain cancer, after demonstrating for the first time that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) is a driving force behind the disease’s aggressive and invasive nature.
Scientists from Virginia Commonwealth University have revealed how two genes interact to kill a wide range of cancer cells. Originally discovered by the study’s lead investigator Paul B. Fisher, M.Ph., Ph.D., the genes known as mda-7/IL-24 and SARI could potentially be harnessed to treat both primary and metastatic forms of brain, breast, colon, lung, ovary, prostate, skin and other cancers.